European Healthtech startup funding raised during H1 2024.
In H1 2024, 222 European Healthtech companies raised a combined €2.3B across 223 funding rounds, down 22.6% versus H1 2023. UK led by capital raised, and The Future of Health Grant (FoHG) program was the most active investor. Data as of 9 Jul 2026.
22 exits · €523M disclosed.
| Calypso Biotech | Acquisition | Jan 2024 | €425M |
| Sonio | Acquisition | May 2024 | €86M |
| Apotea | Acquisition | Jan 2024 | €12M |
| €61M |
| Oculis | Other | Apr 2024 | €55M |
| Infinite Roots (Mushlabs) | Series B | Jan 2024 | €53M |
| Natural Cycles | Series C | May 2024 | €51M |
| Uromems | Series C | Jun 2024 | €44M |
| Grey Wolf Therapeutics | Series B | May 2024 | €42M |
| LabGenius | Other | May 2024 | €41M |
| Bob W | Series B | Feb 2024 | €40M |
| Phagenesis | Series D+ | Mar 2024 | €39M |
| Enifer | Series B | May 2024 | €36M |
| Relation Therapeutics | Seed | Mar 2024 | €32M |
| Enterprise Therapeutics | Series B | Jan 2024 | €30M |